Document is current
Any future updates will be listed below
-
Authors
Al Bakir, Maise https://orcid.org/0000-0002-0846-8332
Huebner, Ariana https://orcid.org/0000-0001-8009-4999
Martínez-Ruiz, Carlos https://orcid.org/0000-0002-4817-0565
Grigoriadis, Kristiana https://orcid.org/0000-0002-8435-0176
Watkins, Thomas B. K.
Pich, Oriol https://orcid.org/0000-0002-1956-1882
Moore, David A. https://orcid.org/0000-0002-6296-1312
Veeriah, Selvaraju
Ward, Sophia https://orcid.org/0000-0002-6777-5279
Laycock, Joanne https://orcid.org/0000-0003-3005-1442
Johnson, Diana
Rowan, Andrew
Razaq, Maryam
Akther, Mita
Naceur-Lombardelli, Cristina
Prymas, Paulina
Toncheva, Antonia
Hessey, Sonya https://orcid.org/0000-0001-9856-424X
Dietzen, Michelle https://orcid.org/0000-0002-6853-7563
Colliver, Emma https://orcid.org/0000-0002-1497-0740
Frankell, Alexander M. https://orcid.org/0000-0002-0341-7878
Bunkum, Abigail https://orcid.org/0000-0002-7753-9421
Lim, Emilia L.
Karasaki, Takahiro https://orcid.org/0000-0001-6863-2360
Abbosh, Christopher https://orcid.org/0000-0002-8983-1382
Hiley, Crispin T.
Hill, Mark S. https://orcid.org/0000-0003-0718-8934
Cook, Daniel E. https://orcid.org/0000-0003-3347-562X
Wilson, Gareth A.
Salgado, Roberto https://orcid.org/0000-0002-1110-3801
Nye, Emma
Stone, Richard Kevin
Fennell, Dean A.
Price, Gillian
Kerr, Keith M.
Naidu, Babu
Middleton, Gary https://orcid.org/0000-0001-5695-3474
Summers, Yvonne
Lindsay, Colin R.
Blackhall, Fiona H.
Cave, Judith
Blyth, Kevin G.
Nair, Arjun
Ahmed, Asia
Taylor, Magali N.
Procter, Alexander James
Falzon, Mary
Lawrence, David
Navani, Neal https://orcid.org/0000-0002-6412-7516
Thakrar, Ricky M.
Janes, Sam M. https://orcid.org/0000-0002-6634-5939
Papadatos-Pastos, Dionysis
Forster, Martin D.
Lee, Siow Ming
Ahmad, Tanya
Quezada, Sergio A. https://orcid.org/0000-0002-9763-1700
Peggs, Karl S.
Van Loo, Peter https://orcid.org/0000-0003-0292-1949
Dive, Caroline
Hackshaw, Allan https://orcid.org/0000-0002-5570-5070
Birkbak, Nicolai J. https://orcid.org/0000-0003-1613-9587
Zaccaria, Simone https://orcid.org/0000-0002-5265-7392
,
Lester, Jason F.
Bajaj, Amrita
Nakas, Apostolos
Sodha-Ramdeen, Azmina
Ang, Keng
Tufail, Mohamad
Chowdhry, Mohammed Fiyaz
Scotland, Molly
Boyles, Rebecca
Rathinam, Sridhar
Wilson, Claire
Marrone, Domenic
Dulloo, Sean
Matharu, Gurdeep
Shaw, Jacqui A.
Riley, Joan
Primrose, Lindsay
Boleti, Ekaterini
Cheyne, Heather
Khalil, Mohammed
Richardson, Shirley
Cruickshank, Tracey
Benafif, Sarah
Gilbert, Kayleigh
Patel, Akshay J.
Osman, Aya
Lacson, Christer
Langman, Gerald
Shackleford, Helen
Djearaman, Madava
Kadiri, Salma
Leek, Angela
Hodgkinson, Jack Davies
Totten, Nicola
Montero, Angeles
Smith, Elaine
Fontaine, Eustace
Granato, Felice
Doran, Helen
Novasio, Juliette
Rammohan, Kendadai
Joseph, Leena
Bishop, Paul
Shah, Rajesh
Moss, Stuart
Joshi, Vijay
Crosbie, Philip
Gomes, Fabio
Brown, Kate
Carter, Mathew
Chaturvedi, Anshuman
Priest, Lynsey
Oliveira, Pedro
Krebs, Matthew G.
Clipson, Alexandra
Tugwood, Jonathan
Kerr, Alastair
Rothwell, Dominic G.
Kilgour, Elaine
Aerts, Hugo J. W. L.
Schwarz, Roland F.
Kaufmann, Tom L.
Rosenthal, Rachel
Szallasi, Zoltan
Kisistok, Judit
Sokac, Mateo
Diossy, Miklos
Demeulemeester, Jonas
Stewart, Aengus
Magness, Alastair
Karamani, Angeliki
Chain, Benny
Campbell, Brittany B.
Castignani, Carla
Bailey, Chris
Puttick, Clare
Weeden, Clare E.
Lee, Claudia
Richard, Corentin
Pearce, David R.
Karagianni, Despoina
Biswas, Dhruva
Levi, Dina
Hoxha, Elena
Larose Cadieux, Elizabeth
Grönroos, Eva
Gálvez-Cancino, Felip
Athanasopoulou, Foteini
Gimeno-Valiente, Francisco
Kassiotis, George
Stavrou, Georgia
Mastrokalos, Gerasimos
Zhai, Haoran
Lowe, Helen L.
Matos, Ignacio
Goldman, Jacki
Reading, James L.
Black, James R. M.
Herrero, Javier
Rane, Jayant K.
Nicod, Jerome
Lam, Jie Min
Hartley, John A.
Enfield, Katey S. S.
Selvaraju, Kayalvizhi
Thol, Kerstin
Litchfield, Kevin
Ng, Kevin W.
Chen, Kezhong
Dijkstra, Krijn
Thakkar, Krupa
Ensell, Leah
Shah, Mansi
Vasquez, Marcos
Litovchenko, Maria
Werner Sunderland, Mariana
Leung, Michelle
Escudero, Mickael
Angelova, Mihaela
Tanić, Miljana
Sivakumar, Monica
Kanu, Nnennaya
Chervova, Olga
Lucas, Olivia
Al-Sawaf, Othman
Hobson, Philip
Pawlik, Piotr
Bentham, Robert
Hynds, Robert E.
Vendramin, Roberto
Saghafinia, Sadegh
López, Saioa
Gamble, Samuel
Ung, Seng Kuong Anakin
Vanloo, Sharon
Boeing, Stefan
Beck, Stephan
Bola, Supreet Kaur
Denner, Tamara
Marafioti, Teresa
Mourikis, Thanos P.
Spanswick, Victoria
Barbè, Vittorio
Lu, Wei-Ting
Hill, William
Liu, Wing Kin
Wu, Yin
Naito, Yutaka
Ramsden, Zoe
Veiga, Catarina
Royle, Gary
Collins-Fekete, Charles-Antoine
Fraioli, Francesco
Ashford, Paul
Clark, Tristan
Borg, Elaine
Wilson, James
Patrini, Davide
Martinoni Hoogenboom, Emilie
Monk, Fleur
Holding, James W.
Choudhary, Junaid
Bhakhri, Kunal
Scarci, Marco
Hayward, Martin
Panagiotopoulos, Nikolaos
Gorman, Pat
Khiroya, Reena
Stephens, Robert C. M.
Wong, Yien Ning Sophia
Bandula, Steve
Sharp, Abigail
Smith, Sean
Gower, Nicole
Dhanda, Harjot Kaur
Chan, Kitty
Pilotti, Camilla
Leslie, Rachel
Grapa, Anca
Zhang, Hanyun
AbdulJabbar, Khalid
Pan, Xiaoxi
Yuan, Yinyin
Chuter, David
MacKenzie, Mairead
Chee, Serena
Alzetani, Aiman
Scarlett, Lydia
Richards, Jennifer
Ingram, Papawadee
Austin, Silvia
Lim, Eric
De Sousa, Paulo
Jordan, Simon
Rice, Alexandra
Raubenheimer, Hilgardt
Bhayani, Harshil
Ambrose, Lyn
Devaraj, Anand
Chavan, Hema
Begum, Sofina
Buderi, Silviu I.
Kaniu, Daniel
Malima, Mpho
Booth, Sarah
Nicholson, Andrew G.
Fernandes, Nadia
Shah, Pratibha
Proli, Chiara
Hewish, Madeleine
Danson, Sarah
Shackcloth, Michael J.
Robinson, Lily
Russell, Peter
Dick, Craig
Le Quesne, John
Kirk, Alan
Asif, Mo
Bilancia, Rocco
Kostoulas, Nikos
Thomas, Mathew
Jamal-Hanjani, Mariam https://orcid.org/0000-0003-1212-1259
McGranahan, Nicholas https://orcid.org/0000-0001-9537-4045
Swanton, Charles https://orcid.org/0000-0002-4299-3018
- License Information
-
More Information
Article History
Received: 21 October 2021
Accepted: 12 January 2023
First Online: 12 April 2023
Competing interests
: M.A.B. has consulted for Achilles Therapeutics. D.A.M. reports speaker fees from AstraZeneca, Eli Lilly and Takeda, consultancy fees from AstraZeneca, Thermo Fisher Scientific, Takeda, Amgen, Janssen, MIM Software, Bristol Myers Squibb (BMS) and Eli Lilly and has received educational support from Takeda and Amgen. S.V. is listed as a co-inventor on a patent for detecting molecules in a sample (U.S. patent no. 10578620). A.M.F. is listed as a co-inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). C.A. has received speaking honoraria or expenses from Novartis, Roche, AstraZeneca and BMS and reports employment at AstraZeneca; is listed as an inventor on a European patent application relating to assay technology to detect tumour recurrence (PCT/GB2017/053289), the patent has been licensed to commercial entities and, under his terms of employment, C.A is due a revenue share of any revenue generated from such license(s); declares a patent application (PCT/US2017/028013) for methods to detect lung cancer; and is a named inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987); and is a named inventor on a provisional patent protection related to a ctDNA detection algorithm. C.T.H. has received speaker fees from AstraZeneca. G.A.W. is employed by and has stock options in Achilles Therapeutics. R.S. reports non-financial support from Merck and BMS, research support from Merck, Puma Biotechnology and Roche, and personal fees from Roche, BMS and Exact Sciences for advisory boards. D.A.F reports grants from Aldeyra, Boehringer Ingelheim, Astex Therapeutics, Bayer, BMS, GSK, RS Oncology, Clovis, Eli Lilly, BMS, MSD and GSK, and personal fees from Atara, BMS, Boehringer Ingelheim, Cambridge Clinical Laboratories, Targovax, Roche and RS Oncology. C.R.L. has provided consulting/advisory support to Amgen and Hanson Wade, and educational support to Amgen; and has received financial support for research from Revolution Medicines, as well as non-financial support from Amgen. J.C. reports funding from Amgen to attend a conference. A.N. reports personal fees from Aidence BV and Faculty Science Limited. N.N. reports honoraria for non-promotional educational talks, advisory boards or conference attendance from Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Fujifilm, Guardant Health, Intuitive, Janssen, Lilly, Merck Sharp & Dohme, Olympus, OncLive, PeerVoice, Pfizer and Takeda. S.M.J. has received fees for advisory board membership in the last three years from Astra-Zeneca, Bard1 Lifescience and Johnson and Johnson, grant income from Owlstone and GRAIL, and assistance with travel to an academic meeting from Cheisi. M.D.F. acknowledges grant support from CRUK, AstraZeneca, Boehringer Ingelheim, MSD and Merck; is an advisory board member for Transgene; and has consulted for Achilles, Amgen, AstraZeneca, Bayer, Boxer, BMS, Celgene, EQRx, Guardant Health, Immutep, Ixogen, Janssen, Merck, MSD, Nanobiotix, Novartis, Oxford VacMedix, Pharmamar, Pfizer, Roche, Takeda and UltraHuman. S.A.Q. is a co-founder, stockholder and chief scientific officer of Achilles Therapeutics. K.S.P is a co-founder of Achilles Therapeutics. C.D. received research funding/educational research grants from AstraZeneca, Astex Pharmaceuticals, Bioven, Amgen, Carrick Therapeutics, Merck, Taiho Oncology, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene, Epigene Therapeutics, Angle, Menarini, Clearbridge Biomedics, Thermo Fisher Scientific and Neomed Therapeutics; and received honoraria for consultancy and/or advisory boards from Biocartis, Merck, AstraZeneca, GRAIL and Boehringer Ingelheim. A.Ha. has received fees for being a member of independent data monitoring committees for Roche-sponsored clinical trials, and academic projects co-ordinated by Roche. N.J.B. is listed as a co-inventor on a patent to identify responders to cancer treatment (PCT/GB2018/051912) and a co-inventor on a patent for methods for predicting anti-cancer response (US14/466,208). M.J.-H. has consulted for, and is a member of, the Achilles Therapeutics scientific advisory board and steering committee, has received speaker honoraria from Pfizer, Astex Pharmaceuticals and Oslo Cancer Cluster, and is listed as a co-inventor on a European patent application relating to methods to detect lung cancer PCT/US2017/028013); this patent has been licensed to commercial entities and, under terms of employment, M.J.-H. is due a share of any revenue generated from such license(s). N.M. has received consultancy fees and has stock options in Achilles Therapeutics; and holds European patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), and predicting survival rates of patients with cancer (PCT/GB2020/050221). C.S. acknowledges grant support from AstraZeneca, Boehringer-Ingelheim, BMS, Pfizer, Roche-Ventana, Invitae (previously Archer Dx, collaboration in minimal residual disease sequencing technologies), Ono Pharmaceutical, and Personalis; is an AstraZeneca advisory board member and chief investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also co-chief investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s scientific advisory board; receives consultant fees from Achilles Therapeutics (also a scientific advisory board member), Bicycle Therapeutics (also a scientific advisory board member), Genentech, Medicxi, China Innovation Centre of Roche (CICoR) formerly Roche Innovation Centre – Shanghai, Metabomed (until July 2022) and the Sarah Cannon Research Institute; has received honoraria from Amgen, AstraZeneca, Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Illumina, and Roche-Ventana; had stock options in Apogen Biotechnologies and GRAIL until June 2021, and currently has stock options in Epic Bioscience, Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics; is listed as an inventor on a European patent application relating to assay technology to detect tumour recurrence (PCT/GB2017/053289), the patent has been licensed to commercial entities and, under his terms of employment, C.S. is due a revenue share of any revenue generated from such license(s); holds patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US patent relating to detecting tumour mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1) and both a European and US patent related to identifying insertion/deletion mutation targets (PCT/GB2018/051892) and is listed as a co-inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987) and is a named inventor on a provisional patent protection related to a ctDNA detection algorithm.
